Trials / Completed
CompletedNCT01547546
A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This open-label, multicenter, Phase I, dose-escalating study will evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics and efficacy of GDC-0084 in patients with progressive or recurrent high-grade glioma. Stage 1 is the dose escalation part of the study. Stage 2, patients will receive GDC-0084 at a recommended dose for future studies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GDC-0084 | Multiple doses |
Timeline
- Start date
- 2012-04-01
- Primary completion
- 2015-01-01
- Completion
- 2015-01-01
- First posted
- 2012-03-08
- Last updated
- 2016-11-02
Locations
5 sites across 2 countries: United States, Spain
Source: ClinicalTrials.gov record NCT01547546. Inclusion in this directory is not an endorsement.